GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

Tsubota Laboratory 4890.T · JPY

Health Care · Tokyo Stock Exchange · 🇯🇵 Japan

Compare

229

+3.62%

Close of 9 Nov 2026, in JPY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Tsubota Laboratory

Its shares trade on Tokyo Stock Exchange under the ticker 4890.T. It has been listed since 23 June 2022. In the fiscal year to 31 March 2026, it reported revenue of ¥200.0m and a net loss of ¥761.8m. At that date it held total assets of ¥1.32bn and shareholders' equity of ¥863.9m.

Tsubota Laboratory, Inc. engages in research and development of pharmaceuticals and medical devices related to the treatment of myopia, dry eye, presbyopia, and related cases. The company is headquartered in Shinjuku, Tokyo-To. The company went IPO on 2022-06-23. The firm operates with a B2B business model. The model generates revenue from lump-sum payments under joint research and development agreements and licensing agreements with partner companies, milestone payments, and royalties under post-commercialization (post-launch) loyalty agreements and creates new value by investing the profits in the new research. The firm is also engaged in the research and development of products for adults that treat depression and dementia, improve sleep and increase concentration.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
23 Jun 2022
Employees
10

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Tsubota Laboratory Inc. focuses on myopia and dry eye treatments with 10 employees.
  • B2B model generates revenue through R&D agreements and licensing deals.
  • Invests profits into new research for depression and dementia treatments.

Weaknesses

  • Small team of 10 employees limits R&D capacity and market reach.
  • Limited revenue streams from only B2B agreements and licensing.
  • No commercialized products yet, relying on future milestone payments.

Opportunities

  • Growing demand for myopia treatments in Japan's aging population.
  • Expanding R&D into depression and dementia therapies with high market potential.
  • Collaborations with partner companies for joint development agreements.

Threats

  • Competition from established pharmaceutical firms in Japan.
  • Regulatory delays in approving new medical devices and drugs.
  • Economic downturns affecting B2B investment in R&D projects.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.